Treatment of chronic alopecia areata with tildrakizumab: an open‐label pilot study

Alopecia universalis improvement following risankizumab in a psoriasis patient

“…Stromal melanocytes are most abundant near the collarette. 4 We identified blue-grey periphery, with a blue collarette and absence of freckles as the iris pattern most associated with skin cancer in our population. Green iris periphery was found in 11.2% (n = 19) and was not significantly associated with skin cancer.…”

“…Available treatments show a very variable degree of efficacy and frequent unsatisfactory results. 4 A recent trial showed anti-IL 23 (tildrakizumab) as an efficacious therapy in patients not responsive to multiple treatments such as oral prednisolone, azathioprine intralesional steroid and diphenylcyclo-propenone (DPCP). 4 Here, we report the case of a 35 year-old man who attended our clinic in March 2021 suffering from psoriasis and alopecia universalis.…”

“…4 A recent trial showed anti-IL 23 (tildrakizumab) as an efficacious therapy in patients not responsive to multiple treatments such as oral prednisolone, azathioprine intralesional steroid and diphenylcyclo-propenone (DPCP). 4 Here, we report the case of a 35 year-old man who attended our clinic in March 2021 suffering from psoriasis and alopecia universalis. The patient reported that alopecia had started about 12 years ago presenting a chronic-remitting course, without any significant and durable improvement with topical/systemic corticosteroids, cyclosporine or DPCP.…”

Alopecia areata: a review of diagnosis, pathogenesis and the therapeutic landscape

“…However, development of new AA and exacerbation of pre-existing AA has also been reported with dupilumab use 40 . Tildrakizumab, a high-affinity monoclonal antibody targeting IL-23, was of little benefit in patients with chronic AA 46 . Similarly, ustekinumab, an IL-12/IL-23p40 monoclonal antibody, showed mixed reports, both improving and exacerbating disease 47 .…”

A Review of the Efficacy and Safety for Biologic Agents Targeting IL-23 in Treating Psoriasis With the Focus on Tildrakizumab

“…Treatment of alopecia areata with tildrakizumab 100 mg administered at weeks 0, 4, and 16 has also been reported. Nine patients with alopecia areata were treated with tildrakizumab 100 mg, where 2 patients had a partial response (16–99% improvement) with 2 patients experiencing AEs including URTIs and acne ( 168 ). Finally, a patient with recalcitrant lichen planopilaris and frontal fibrosing alopecia demonstrated significant improvement after 4 doses of tildrakizumab 100 mg at weeks 0, 4, and subsequently every 12 weeks.…”